Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 12, 2011, Pages 3788-3793

  Kinoshita, Kazutomo ^a   Ono, Yoshiyuki ^a   Emura, Takashi ^a   Asoh, Kohsuke ^a   Furuichi, Noriyuki ^a   Ito, Toshiya ^a   Kawada, Hatsuo ^a   Tanaka, Shota ^a   Morikami, Kenji ^a   Tsukaguchi, Toshiyuki ^a   Sakamoto, Hiroshi ^a   Tsukuda, Takuo ^a   Oikawa, Nobuhiro ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anaplastic lymphoma kinase; Antitumor efficacy; Kinase inhibitors

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TETRACYCLIC COMPOUND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CHEMICAL REACTION; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; ISOMERISM; MOUSE; NONHUMAN; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; ENZYME ACTIVATION; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR STRUCTURE; RECEPTOR PROTEIN-TYROSINE KINASES; TETRACYCLINES;

MUS;

EID: 79957869630     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.04.020     Document Type: Article

References (20)

1. Morris, S. W.; Kirstein, M. N.; Valentine, M. B.; Dittmer, K. G.; Shapiro, D. N.; Saltman, D. L.; Look, A. T. Science 1994, 263, 1281.
2. Webb, T. R.; Slavish, J.; George, R. E.; Look, A. T.; Xue, L.; Jiang, Q.; Cui, X.; Rentrop, W. B.; Morris, S. W. Expert Rev. Anticancer Ther. 2009, 9, 331.
3. Pulford, K.; Lamant, L.; Morris, S. W.; Butler, L. H.; Wood, K. M.; Stroud, D.; Delsol, G.; Mason, D. Y. Blood 1997, 89, 1394.
4. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Nature 2007, 448, 561.
5. Soda, M.; Takada, S.; Takeuchi, K.; Choi, Y. L.; Enomoto, M.; Ueno, T.; Haruta, H.; Hamada, T.; Yamashita, Y.; Ishikawa, Y.; Sugiyama, Y.; Mano, H. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 19893.
6. Scott, J. R.; Shapiro, G. I. Curr. Opin. Invest. Drugs 2010, 11, 1477.
7. Osajima-Hakomori, Y.; Miyake, I.; Ohira, M.; Nakagawara, A.; Nakagawa, A.; Sakai, R. Am. J. Pathol. 2005, 167, 213.
8. Mossé, Y. P.; Laudenslager, M.; Longo, L.; Cole, K. A.; Wood, A.; Attiyeh, E. F.; Laquaglia, M. J.; Sennett, R.; Lynch, J. E.; Perri, P.; Laureys, G.; Speleman, F.; Kim, C.; Hou, C.; Hakonarson, H.; Torkamani, A.; Schork, N. J.; Brodeur, G. M.; Tonini, G. P.; Rappaport, E.; Devoto, M.; Maris, J. M. Nature 2008, 455, 930.
9. Bossi, R. T.; Saccardo, M. B.; Ardini, E.; Menichincheri, M.; Rusconi, L.; Magnaghi, P.; Orsini, P.; Avanzi, N.; Borgia, A. L.; Nesi, M.; Bandiera, T.; Fogliatto, G.; Bertrand, J. A. Biochemistry 2010, 49, 6813.
10. Milkiewicz, K. L.; Weinberg, L. R.; Albom, M. S.; Angeles, T. S.; Cheng, M.; Ghose, A. K.; Roemmele, R. C.; Theroff, J. P.; Underiner, T. L.; Zificsak, C. A.; Dorsey, B. D. Bioorg. Med. Chem. 2010, 18, 4351.
11. Sabbatini, P.; Korenchuk, S.; Rowand, J. L.; Groy, A.; Liu, Q.; Leperi, D.; Atkins, C.; Dumble, M.; Yang, J.; Anderson, K.; Kruger, R. G.; Gontarek, R. R.; Maksimchuk, K. R.; Suravajjala, S.; Lapierre, R. R.; Shotwell, J. B.; Wilson, J. W.; Chamberlain, S. D.; Rabindran, S. K.; Kumar, R. Mol. Cancer Ther. 2009, 8, 2811.
12. Ott, G. R.; Tripathy, R.; Cheng, M.; McHugh, R.; Anzalone, A. V.; Underiner, T. L.; Curry, M. A.; Quail, M. R.; Lu, L.; Wan, W.; Angeles, T. S.; Albom, M. S.; Aimone, L. D.; Ator, M. A.; Ruggeri, B. A.; Dorsey, B. D. ACS Med. Chem. Lett. 2010, 1, 493.
13. 2 using time-resolved fluorescence resonance energy transfer (TR-FRET) assay.
14. Fleming, F. F.; Yao, L.; Ravikumar, P. C.; Funk, L.; Shook, B. C. J. Med. Chem. 2010, 53, 7902.
15. Cell growth inhibitory assay: KARPAS-299 cells were treated with various concentrations of assay compounds for 96 h. Cell growth inhibition was determined by cell counting kit-8 assay.
16. Microsomal stability assay: 1 μM of each compound was incubated with human (or mouse) liver microsome (0.5 mg protein/mL) in 50 mM phosphate buffer (pH 7.4) containing 1 mM NADPH (the reduced form of nicotinamide adenine dinucleotide phosphate) at 37 °C for 30 min. After the enzyme reaction was terminated with the addition of a three-fold volume of acetonitrile, the reaction mixture was centrifuged at 1500 rpm for 10 min. The resultant supernatant was used as a test sample to measure the stability in human (or mouse) liver microsome by quantitating the compound in the sample using LC/MS.
17. Wuitschik, G.; Carreira, E. M.; Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Müller, K. J. Med. Chem. 2010, 53, 3227.
18. The quantity of enzyme and ATP and the kind of substrate and cation species added in each assay are given in Supplementary Table 1.
19. 0 x 100, where W and W0 are the body weight on a specific experimental day and on the first day of treatment, respectively.
20. Hart, H.; Corbin, J. L.; Wagner, C. R.; Wu, C-Y. J. Am. Chem. Soc. 1963, 85, 3269.